AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 8, 2025

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.

Business Wire • Dec 8, 2025

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

AbCellera Biologics Inc. ( ABCL ) Jefferies London Healthcare Conference 2025 November 20, 2025 8:00 AM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Presentation Unknown Analyst Great.

Seeking Alpha • Nov 22, 2025

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Stephen Quake to its Board of Directors.

Business Wire • Nov 10, 2025

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

AbCellera Biologics Inc. ( ABCL ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Tryn Stimart - Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer Carl L. Hansen - CEO, President & Chairperson Andrew Booth - Chief Financial Officer Conference Call Participants Malcolm Hoffman - BMO Capital Markets Equity Research Andrea Tan - Goldman Sachs Group, Inc., Research Division Joshua Nickerson - Stifel, Nicolaus & Company, Incorporated, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Jacqueline Kisa - TD Cowen, Research Division Presentation Operator Good afternoon, and welcome to AbCellera's Third Quarter 2025 Business Update Conference Call.

Seeking Alpha • Nov 8, 2025

AbCellera Reports Q3 2025 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2025 Business Results.

Business Wire • Nov 6, 2025

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.17 per share a year ago.

Zacks Investment Research • Nov 6, 2025

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in November and December 2025.

Business Wire • Oct 7, 2025

AbCellera Biologics: Entering Growth Phase After A Pause

AbCellera Biologics is poised for long-term growth as its clinical manufacturing facility nears completion, enabling in-house drug development and contract manufacturing revenue. ABCL's strategic pivot from a service provider to a proprietary drug developer targets high-growth monoclonal antibody markets, with promising candidates ABCL635 and ABCL575 entering clinical trials. Despite recent revenue and net income declines due to the business model shift, ABCL is well-funded and expects revenue to double in 2026 as clinical batches commence.

Seeking Alpha • Oct 6, 2025

Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?

Here is how AbCellera Biologics Inc. (ABCL) and Astrazeneca (AZN) have performed compared to their sector so far this year.

Zacks Investment Research • Sep 30, 2025